The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Zanidatamab: HER2-targeting bispecific antibody in HER2-expressing GEA
Anthony B. El-Khoueiry, MD, Keck School of Medicine of USC, Los Angeles, CA, presents the results of a Phase I study evaluating zanidatamab, a HER2-targeting bispecific antibody in HER2-expressing gastroesophageal adenocarcinoma (GEA). Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy) and further investigation in HER2-expressing GEA is ongoing. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
